BCRX Bathi mangsa ngarep BioCryst Pharmaceuticals, Inc.
The stability of BioCryst (BCRX) is underpinned by robust developments in protein crystallography and oral molecules. The projected profit trend demonstrates business resilience, while 0.14 captures the magnitude of this parameter. Revenues are based on insurance payouts for the treatment of rare genetic pathologies. Operational efficiency is increasing through the outsourcing of logistics to specialized third-party operators.
Rincian analitis perusahaan BioCryst
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- informasi kapitalisasi buku:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas BioCryst|BCRX - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas BioCryst Pharmaceuticals Inc|BCRX - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku BioCryst|BCRX - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioCryst|Rasio cepet biocryst.com
- informasi bathi lan kelipatan valuasi:
BCRX - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep BioCryst|BCRX - Periode bali modal bisnis|Rega marang bathi mangsa ngarep BioCryst Pharmaceuticals|BCRX - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA BioCryst|BCRX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan BioCryst|BCRX - Bathi saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan biocryst.com|BCRX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep BioCryst
Analisis dhasar perusahaan:BCRX, BioCryst
BioCryst (BCRX) projected profit measures the expected net remaining funds after deducting all operating expenses and taxes, reflecting future capital generation efficiency. High margins for the angioedema treatment and patent protection through the end of the decade drive the upward trend in prospective net income, confirming the issuer's financial stability and the asset's growth potential.
Perusahaan pesaing
ARGX (argenx SE) - Proyeksi bathi mangsa ngarep|Proyeksi bathi mangsa ngarep biontech.de|Bathi mangsa ngarep ABVX (Abivax Corp)|ADMA (ADMA Biologics Inc) - Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep PTGX (Protagonist Therapeutics Inc)|Prakiraan bathi perusahaan Immunovant Therapeutics (IMVT)|KNSA - Bathi sing dikarepake|grifols.com (GRFS) - Bathi mangsa ngarep|Adaptive Biotechnologies Corporation (ADPT) - Bathi sing dikarepake|Bathi mangsa ngarep Celldex Therapeutics Inc|Bathi mangsa ngarep AUPH|Proyeksi bathi mangsa ngarep Vera Corp|Bathi sing dikarepake Dianthus Therapeutics (DNTH)|pharvaris.com - Prakiraan bathi resik|Proyeksi bathi mangsa ngarep ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Bathi resik sing dikarepake|Intrexon - Proyeksi bathi mangsa ngarep|PHAR: Bathi sing dikarepake|NKTR: Proyeksi bathi mangsa ngarep|UPB - Prakiraan bathi perusahaan|Bathi sing dikarepake Zenas Biopharma|Bathi resik sing dikarepake Immunome Inc IMNM|Proyeksi bathi mangsa ngarep GOSS|Bathi mangsa ngarep KalVista Corp KALV|Bathi sing dikarepake Septerna Inc SEPN|Penghasilan resik sing dikarepake PVLA|SVRA: Bathi mangsa ngarep|Bathi resik sing dikarepake Rigel Pharma|AnaptysBio Corp (ANAB) - Bathi sing dikarepake|ATXS - Prakiraan bathi perusahaan|Bathi mangsa ngarep ENGN|RAPT (rapt.com) - Bathi resik mangsa ngarep|Proyeksi bathi mangsa ngarep JBIO|Bathi sing dikarepake ACRS (Aclaris Therapeutics Inc.)|Proyeksi bathi mangsa ngarep KYTX (Kyverna)|TLSA - Bathi mangsa ngarep|CABA - Bathi sing dikarepake|Penghasilan resik sing dikarepake VTYX (ventyxbio.com)|THTX (Theratechnologies) - Bathi mangsa ngarep|Prakiraan bathi resik AVTX|Bathi sing dikarepake Eledon|Agenus, Inc - Bathi forward|Proyeksi bathi mangsa ngarep CLYM|ZURA (zurabio.com) - Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep ATYR (aTyr Pharma)|Proyeksi bathi mangsa ngarep Adagene Inc ADAG|IMA - Bathi sing dikarepake|Penghasilan resik sing dikarepake STTK (Shattuck Labs, Inc.)|equilliumbio.com (EQ) - Bathi sing dikarepake|Bathi mangsa ngarep Connect Biopharma Holdings Limited|IMUX (Immunic Therapeutics) - Proyeksi bathi mangsa ngarep|Proyeksi bathi mangsa ngarep Atara Biotherapeutics Inc|Bathi mangsa ngarep IFRX (InflaRx N.V.)|XFOR (X4 Pharmaceuticals, Inc) - Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep ACET (Adicet Bio, Inc.)|Prakiraan bathi perusahaan Celularity Inc (CELU)|INMB - Bathi sing dikarepake|Barinthus Biotherapeutics PLC (BRNS) - Bathi mangsa ngarep|Kezar Life Sciences, Inc (KZR) - Bathi sing dikarepake|Bathi mangsa ngarep SAB Biotherapeutics Inc|Bathi mangsa ngarep AKTX|Proyeksi bathi mangsa ngarep Enlivex Therapeutics, Ltd.|Bathi sing dikarepake Q32 Bio Inc. (QTTB)|GeoVax Labs - Prakiraan bathi resik|Proyeksi bathi mangsa ngarep EDSA (Edesa)|iBio Corporation (IBIO) - Bathi resik sing dikarepake|Carisma Tx - Proyeksi bathi mangsa ngarep|XTLB: Bathi sing dikarepake|BOLT: Proyeksi bathi mangsa ngarep|HCWB - Prakiraan bathi perusahaan|Bathi sing dikarepake Aptevo Therapeutics, Inc.|Bathi resik sing dikarepake aimimmuno.com AIM|Proyeksi bathi mangsa ngarep ADTX|Bathi mangsa ngarep gribio.com GRI|Bathi sing dikarepake XORTX Therapeutics XRTX|Penghasilan resik sing dikarepake HIND|REVB: Bathi mangsa ngarep|Bathi resik sing dikarepake Indaptus Corp|Scinai Immunotherapeutics (SCNI) - Bathi sing dikarepake|CALI - Prakiraan bathi perusahaan|Bathi mangsa ngarep AFMD|ALLK (Allakos Therapeutics) - Bathi resik mangsa ngarep|Proyeksi bathi mangsa ngarep HOOK|Bathi sing dikarepake IGMS (igmbio.com)|Proyeksi bathi mangsa ngarep ITOS (iTeos Therapeutics)|OCEA - Bathi mangsa ngarep|TCBP - Bathi sing dikarepake|Penghasilan resik sing dikarepake THRD (Third Harmonic Bio Inc.)
